Tumor Targets Equipment
-
by CDR-Lifebased in SWITZERLAND
a series of highly cancer-targeted and drug-based immunotherapies against intracellular tumor antigens for treatment of a variety of solid tumor malignancies. In addition, the company has a superior trispecific BCMA therapy positioned for partnering as well as a therapeutic antibody fragment for treatment of a blinding retinal disease, which is ...
-
based in SWITZERLAND
T3 Pharma has developed a proprietary cancer therapy platform based on regulating and harnessing the natural behaviours of live bacteria. The genetically engineered bacteria selectively target solid tumors, where they deliver chosen protein payloads into the ...
-
Manufactured by CytomX Therapeutics, Inc.based in USA
Probody therapeutics are designed to outsmart cancer by exploiting the unique conditions of the tumor microenvironment to more effectively localize treatment to the tumor, while limiting activity in healthy tissues. These novel therapies are designed to take advantage of high levels of protease activity in the tumor microenvironment. Their ...
-
Manufactured by Celularity Inc.based in USA
CYNK-CAR candidates are being developed as allogeneic, off-the-shelf approaches through gene modification of human placental hematopoietic stem cell-derived natural killer (NK) cells. Various CAR constructs against hematological and solid tumor targets are under pre-clinical ...
-
Manufactured by Mablink Biosciencebased in FRANCE
Antibody–drug conjugates (ADCs) are a unique class of targeted immuno-oncology therapeutics that combine the tumor-targeting selectivity, stability, and favorable pharmacokinetic profile of monoclonal antibodies, with the potent antitumor activity of cytotoxic drugs. The ultimate goal of ADCs is to increase the therapeutic index of ...
-
Manufactured by Immatics N.V.based in GERMANY
Bispecific T cell engaging receptors (TCER®) are off-the-shelf biologics that leverage the body’s immune system by redirecting and activating T cells towards cancer cells expressing specific tumor targets. The design of these novel biologics allows any T cell in the body to become activated and attack the tumor, regardless of the T ...
-
Manufactured by SurgiMabbased in FRANCE
SurgiMab’s tumor-targeting fluorescent molecules enable real time visualization of tumor margins, tumor spread and micro-tumors which are invisible to the naked eye. As opposed to an indiscriminate contrast agent, this ability to specifically highlight malignant tissue during a procedure opens up a broad ...
-
Manufactured by Affimed GmbHbased in GERMANY
The proprietary ROCK platform enables a tumor-targeted approach that can be tailored across hematological and solid tumors. The ROCK (Redirected Optimized Cell Killing) platform allows for a modular approach to generating customizable ICE (innate cell engager) molecules. High-affinity ICE (innate cell engager) molecules, which are created ...
-
Manufactured by Brooklyn ImmunoTherapeutics (BTX)based in USA
IRX-2 is a human-derived mixed cytokine product containing more than 29 cytokines that promote or enhance a complex immune response. Scientists are developing IRX-2 as a cancer immunotherapy. IRX-2 is administered as a subcutaneous injection around lymph node beds near the tumor target. IRX-2 is produced under cGMP (current good ...
-
Manufactured by Eutilex Co.,Ltd.based in SOUTH KOREA
4-1BB mAb-based, tumor antigen targeting bispecific ...
-
Manufactured by Context Therapeutics Inc.based in USA
There is growing interest in applying antibody modalities including bispecifics, antibody-drug conjugates, and CART to solid tumors. However, identifying appropriate tumor-specific targets that avoid adverse effects in healthy tissue has been challenging. The tight junction protein Claudin 6 (CLDN6) is a validated therapeutic ...
-
Manufactured by Fate Therapeutics, Inc.based in USA
NK cells play a major role in the anti-tumor efficacy of certain tumor-antigen targeting antibodies. NK cells express CD16, an activating receptor that binds to the Fc portion of IgG antibodies. Once activated through CD16, NK cells are able to destroy antibody-coated target cells and secrete cytokines, such as interferon gamma, ...
-
based in CANADA
on a target or to multiple targets, resulting in unique mechanisms of action not accessible through typical monospecific antibodies. Azymetric™ bispecific antibodies can block multiple signaling pathways, recruit immune cells to tumors, enhance receptor clustering and internalization, and increase tumor-specific ...
-
Manufactured by Reva Medical LLCbased in USA
TyroSphere beads are bioresorbable embolic microspheres design for using in treating Hypervascular tumors. TyroSphere beads are unique to the market in that they will offer both the advantage of safe degradation/resorption and radiopacity. Meaning that they will visible under standard x-ray to aid precise in delivery to the targeted tumor. ...
-
Manufactured by BriaCell Therapeutics Corp.based in CANADA
Early-Stage Preclinical Program: 30% of all human malignancies display activating RAS mutations with another 60% showing over-activity of Ras-signaling pathways. BriaCell’s novel, proprietary PKCδ inhibitors have shown activity against multiple RAS transformed tumors. This target has an attractive safety profile based on in ...
-
Manufactured by Atlantherabased in FRANCE
Specific targeting of tumor bone tissue, Potent antitumor activity, Low systemic toxicity, Prevention of bone ...
-
Manufactured by Alphageneronbased in USA
An allogenic NK cell therapy that targets tumors expressing mHsp70. Patients are selected with high mHsp70 exosomes in their blood using our Companion Diagnostic AP-CDx (described below). We obtain PBMCs from healthy donors by apheresis, their NK cells are expanded, and incubated ex vivo with TKD and IL-2, followed by freezing, ...
-
Manufactured by Alphageneronbased in USA
Chimeric Antigen Receptor (CAR) NK Cells: Alphageneron is developing ‘off-the- shelf’ umbilical cord (UC) blood- and induced pluripotent stem cell (iPSC)-derived CAR-engineered NK (CAR NK) cell-based cancer therapeutics that target tumors expressing mHsp70, and other (undisclosed) targets. Gene editing of allogeneic CAR NK ...
-
Manufactured by Tactiva Therapeuticsbased in USA
Adoptive Cell Transfer (ACT) is a form of immunotherapy that targets tumors specifically and potently by utilizing large numbers of a patient’s own immune cells to target and destroy cancer cells. Typically, starting with a few immune cells derived from the patient’s blood, billions of cancer fighting immune ...
-
Manufactured by Isotopia Molecular Imagingbased in ISRAEL
Lutetium-177 (Lu-177) is being widely used as a promising radionuclide for targeted therapy and is emerging as a game-changing theranostic isotope for the treatment of neuroendocrine tumors, metastatic castration-resistant prostate cancer (mCRPC) along with its development for new carrier molecules that can provide selective targeting for ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you